Stocks · Health care · In Vitro & In Vivo Diagnostic Substances

Intellia Therapeutics, Inc.

NTLA Clue Score53

United States Fiscal year ends December CIK 0001652130 Results filed 5 Nov 2026

Add to watchlist

What the insiders did Net selling

By person

30 insiders · 298 transactions

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Jean Francois Formela

Director

—

$155.43M (46)

−$155.43M

580,667

0.4144%

$6.96M

−75.9%

John M Leonard

President and CEO

—

$55.08M (60) scheduled

−$55.08M

1,196,479

0.8539%

$14.35M

+127.6%

Novartis Institutes for BioMedical Research, Inc. entity

10% owner

—

$27.87M (1)

−$27.87M

4,129,903

2.95%

$49.52M

−25.9%

Laura Sepp-Lorenzino

EVP, Chief Scientific Officer

—

$19.26M (24) scheduled

−$19.26M

77,388

0.0552%

$927.88K

+1,648%

Caribou Biosciences, Inc. entity

10% owner

—

$14.75M (2)

−$14.75M

3,994,355

2.85%

$47.89M

−28.6%

Jose E Rivera

EVP, General Counsel

—

$9.82M (47) scheduled

−$9.82M

686,808

0.4901%

$8.23M

+29.4%

Glenn Goddard

EVP, Chief Financial Officer

—

$8.79M (16) scheduled

−$8.79M

69,213

0.0494%

$829.86K

—

Nessan Bermingham

President & CEO

—

$7.00M (5)

−$7.00M

458,250

0.3270%

$5.49M

−41.7%

Perry A Karsen

Director

—

$4.75M (3) scheduled

−$4.75M

5,000

0.0036%

$59.95K

—

Atlas Venture Fund IX, L.P. entity

10% owner

—

$2.44M (3)

−$2.44M

3,579,788

2.55%

$42.92M

−19.2%

David Lebwohl

EVP, Chief Medical Officer

—

$2.37M (21) scheduled

−$2.37M

131,192

0.0936%

$1.57M

+2,466%

John F Crowley

Director

—

$1.60M (6) scheduled

−$1.60M

11,716

0.0084%

$140.47K

—

Fred E Cohen

Director

$1.40M (1)

—

+$1.40M

216,653

0.1546%

$2.60M

—

William J Chase

Director

$1.00M (1)

—

+$1.00M

143,893

0.1027%

$1.73M

+2,016%

Eliana Clark

EVP, Chief Technical Officer

—

$690.37K (15)

−$690.37K

93,864

0.0670%

$1.13M

+849.3%

Caroline Dorsa

Director

—

$616.40K (3) scheduled

−$616.40K

12,701

0.0091%

$152.28K

—

James Basta

EVP, General Counsel

—

$499.69K (8)

−$499.69K

156,794

0.1119%

$1.88M

+1,408%

Edward J Dulac III

EVP, Chief Financial Officer

—

$338.80K (4)

−$338.80K

148,175

0.1057%

$1.78M

—

Atlas Venture Associates IX, L.P. entity

10% owner

—

$293.84K (2)

−$293.84K

3,729,788

2.66%

$44.72M

−0.6%

Derek Hicks

EVP, Chief Business Officer

—

$260.84K (3)

−$260.84K

59,878

0.0427%

$717.94K

—

Michael P Dube

VP, Chief Accounting Officer

—

$207.40K (7)

−$207.40K

65,022

0.0464%

$779.61K

+108.3%

Muna Bhanji

Director

—

$95.82K (5) scheduled

−$95.82K

36,403

0.0260%

$436.47K

—

Birgit C Schultes

EVP, Chief Scientific Officer

—

$78.90K (2)

−$78.90K

137,733

0.0983%

$1.65M

+98.3%

Andrew Schiermeier

EVP, Chief Operating Officer

$117.88K (2)

$76.92K (1)

+$40.96K

16,656

0.0119%

$199.71K

+292.7%

Frank Verwiel

Director

—

$37.63K (1) scheduled

−$37.63K

35,148

0.0251%

$421.42K

—

Jesse Goodman

Director

—

$29.07K (2) scheduled

−$29.07K

33,559

0.0239%

$402.37K

—

Jing L. Marantz

EVP, Chief Medical Officer

—

—

—

199,822

0.1426%

$2.40M

—

Georgia Keresty

Director

—

—

—

41,083

0.0293%

$492.59K

—

Brian Goff

Director

—

—

—

32,609

0.0233%

$390.98K

—

Graeme Bell

EVP, Chief Financial Officer

—

—

—

21,400

0.0153%

$256.59K

—